Predictors of three-month mortality and severe chemotherapy-related adverse events in patients aged 70 years and older with metastatic non-small-cell lung cancer: A secondary analysis of ESOGIA-GFPC-GECP 08-02 study.
暂无分享,去创建一个
F. Guisier | R. Corre | E. Paillaud | F. Canouï-Poitrine | L. Greillier | O. Bylicki | C. Ricordel | C. Decroisette | J. Auliac | M. Frelaut | G. Justeau | C. Chouaïd | M. Geier | S. Zebachi | S. Gendarme
[1] C. Tournigand,et al. Energy expenditure profiles and the risk of early limiting toxicity in older patients with cancer: The ELCAPA-25 prospective cohort survey. , 2022, Clinical nutrition.
[2] G. Zalcman,et al. Measuring Walking Speed Failed to Predict Early Death and Toxicity in Elderly Patients with Metastatic Non-Small-Cell Lung Cancer (NSCLC) Selected for Undergoing First-Line Systemic Treatment: An Observational Exploratory Study , 2022, Cancers.
[3] S. Plumb,et al. Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study , 2021, The Lancet.
[4] M. Fakih,et al. Geriatric Assessment-Driven Intervention (GAIN) on Chemotherapy-Related Toxic Effects in Older Adults With Cancer: A Randomized Clinical Trial. , 2021, JAMA oncology.
[5] H. Allore,et al. Functional Disability Among Older Versus Younger Adults With Advanced Non–Small-Cell Lung Cancer , 2021, JCO oncology practice.
[6] P. Lorigan,et al. A prospective cohort study on the safety of checkpoint inhibitors in older cancer patients – the ELDERS study , 2021, ESMO open.
[7] K. Lam,et al. The predictive value of G8 and the Cancer and aging research group chemotherapy toxicity tool in treatment-related toxicity in older Chinese patients with cancer. , 2020, Journal of geriatric oncology.
[8] I. Miyashiro,et al. Geriatric assessment domains to predict overall survival in older cancer patients: An analysis of functional status, comorbidities, and nutritional status as prognostic factors , 2020, Cancer medicine.
[9] C. Tournigand,et al. External validation of two predictive scores of chemotherapy toxicities among older patients with solid cancer, from ELCAPA prospective cohort. , 2020 .
[10] S. Mohile,et al. Geriatric assessment and treatment outcomes in older adults with cancer receiving immune checkpoint inhibitors. , 2020, Journal of geriatric oncology.
[11] Y. Rolland,et al. Low lean mass and chemotherapy toxicity risk in the elderly: the Fraction study protocol , 2019, BMC Cancer.
[12] S. Sourdet,et al. Impact of the comprehensive geriatric assessment on treatment decision in geriatric oncology , 2019, BMC Cancer.
[13] Jianying Zhou,et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial , 2019, The Lancet.
[14] F. Barlesi,et al. Functional status in a geriatric oncology setting: A review. , 2019, Journal of geriatric oncology.
[15] Jimmy Ruiz,et al. Frailty assessment predicts toxicity during first cycle chemotherapy for advanced lung cancer regardless of chronologic age. , 2019, Journal of geriatric oncology.
[16] P. V. Van Schil,et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[17] G. Poissonnet,et al. Predicting early death in older adults with cancer. , 2018, European journal of cancer.
[18] S. Novello,et al. Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.
[19] C. Chouaid,et al. Prognostic role of a comprehensive geriatric assessment on the management of elderly patients with advanced non-small cell lung cancer (NSCLC): a pooled analysis of two prospective phase II trials by the GFPC Group. , 2017, Journal of thoracic disease.
[20] C. Tournigand,et al. Prognostic value of the G8 and modified-G8 screening tools for multidimensional health problems in older patients with cancer. , 2017, European journal of cancer.
[21] C. Tournigand,et al. Performance of Four Frailty Classifications in Older Patients With Cancer: Prospective Elderly Cancer Patients Cohort Study. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] J. Daurès,et al. Use of a Comprehensive Geriatric Assessment for the Management of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Phase III Randomized ESOGIA-GFPC-GECP 08-02 Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] L. V. van Elden,et al. Relevance of a Geriatric Assessment for Elderly Patients With Lung Cancer-A Systematic Review. , 2016, Clinical lung cancer.
[24] L. Crinò,et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[25] I. Floriani,et al. Estimating the risk of chemotherapy toxicity in older patients with cancer: The role of the Vulnerable Elders Survey-13 (VES-13). , 2015, Journal of geriatric oncology.
[26] C. Gridelli,et al. Management of elderly patients with NSCLC; updated expert's opinion paper: EORTC Elderly Task Force, Lung Cancer Group and International Society for Geriatric Oncology. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[27] D. Schrijvers,et al. Geriatric screening results and the association with severe treatment toxicity after the first cycle of (radio)chemotherapy. , 2014, Journal of geriatric oncology.
[28] D. McMillan. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. , 2013, Cancer treatment reviews.
[29] G. Colditz,et al. Geriatric assessment is associated with completion of chemotherapy, toxicity, and survival in older adults with cancer. , 2013, Journal of geriatric oncology.
[30] O. Bouché,et al. Geriatric factors predict chemotherapy feasibility: ancillary results of FFCD 2001-02 phase III study in first-line chemotherapy for metastatic colorectal cancer in elderly patients. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] B. V. van Munster,et al. The value of geriatric assessments in predicting treatment tolerance and all-cause mortality in older patients with cancer. , 2012, The oncologist.
[32] S. Mathoulin-Pélissier,et al. Screening older cancer patients: first evaluation of the G-8 geriatric screening tool. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[33] G. Lyman,et al. Predicting the risk of chemotherapy toxicity in older patients: The Chemotherapy Risk Assessment Scale for High‐Age Patients (CRASH) score , 2012, Cancer.
[34] A. Ravaud,et al. Predictors of early death risk in older patients treated with first-line chemotherapy for cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] L. Walter,et al. Impact of age and comorbidity on non-small-cell lung cancer treatment in older veterans. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] Supriya G Mohile,et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] M. Extermann. Basic Assessment of the Older Cancer Patient , 2011, Current treatment options in oncology.
[38] A. Yubero,et al. Assessment of functional status, symptoms and comorbidity in elderly patients with advanced non-small-cell lung cancer (NSCLC) treated with gemcitabine and vinorelbine , 2007, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.
[39] B. Weber,et al. Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[40] R. Pazdur,et al. Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] R. Govindan,et al. Differential prognostic impact of comorbidity. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] J. Wetzels,et al. Assessment of glomerular filtration rate in healthy subjects and normoalbuminuric diabetic patients: validity of a new (MDRD) prediction equation. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[43] M. Extermann,et al. Measurement and impact of comorbidity in older cancer patients. , 2000, Critical reviews in oncology/hematology.
[44] J. Clément,et al. [Development and contribution to the validation of a brief French version of the Yesavage Geriatric Depression Scale]. , 1997, L'Encephale.
[45] Diane Podsiadlo,et al. The Timed “Up & Go”: A Test of Basic Functional Mobility for Frail Elderly Persons , 1991, Journal of the American Geriatrics Society.
[46] S. Folstein,et al. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.
[47] M. Lawton,et al. Assessment of Older People: Self-Maintaining and Instrumental Activities of Daily Living , 1969 .
[48] S. Katz,et al. STUDIES OF ILLNESS IN THE AGED. THE INDEX OF ADL: A STANDARDIZED MEASURE OF BIOLOGICAL AND PSYCHOSOCIAL FUNCTION. , 1963, JAMA.
[49] Y. Fujiwara,et al. Association between the nutritional status and the severity of sarcopenia among community-dwelling elderly Japanese people. , 2016, Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics.